Drug Patents owned by Biogen Inc
1. Drug name - TECFIDERA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399514 | BIOGEN INC | Treatment for multiple sclerosis |
Feb, 2028
(5 years from now) | |
| US10391160 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(12 years from now) | |
| US10994003 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(12 years from now) | |
| US10555993 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(12 years from now) | |
| US10959972 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(13 years from now) | |
| US11007167 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(13 years from now) | |
| US11007166 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(13 years from now) | |
| US11129806 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(13 years from now) | |
Drugs and Companies using DIMETHYL FUMARATE ingredient
Treatment: Method of treating multiple sclerosis; Method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine
Dosage: CAPSULE, DELAYED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 120MG | CAPSULE, DELAYED RELEASE;ORAL | Prescription |
| 240MG | CAPSULE, DELAYED RELEASE;ORAL | Prescription |
2. Drug name - VUMERITY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8669281 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(10 years from now) | |
| US10080733 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(10 years from now) | |
| CN105452213B | BIOGEN INC | Fumaric Acid Ester Prodrugs And Their Use In The Treatment Of Various Diseases In The Application |
Mar, 2034
(11 years from now) | |
| CN105452213A | BIOGEN INC | Fumarate Prodrug And Application In Treating Multiple Disease |
Mar, 2034
(11 years from now) | |
| CN107501110A | BIOGEN INC | Ester Prodrugs And Their Use In The Treatment Of Various Diseases In The Application |
Mar, 2034
(11 years from now) | |
| CN107501110B | BIOGEN INC | Fumaric Acid Ester Prodrugs And The Use Thereof In The Treatment Of Various Diseases |
Mar, 2034
(11 years from now) | |
| EP2970101A4 | BIOGEN INC | Prodrugs Of Fumarates And Their Use In Treating Various Deseases |
Mar, 2034
(11 years from now) | |
| EP2970101A1 | BIOGEN INC | Prodrugs Of Fumarates And Their Use In Treating Various Deseases |
Mar, 2034
(11 years from now) | |
| EP2970101B1 | BIOGEN INC | Prodrugs Of Fumarates And Their Use In Treating Various Deseases |
Mar, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9090558 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(10 years from now) | |
Drugs and Companies using DIROXIMEL FUMARATE ingredient
Treatment: Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 231MG | CAPSULE, DELAYED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.